ARCHIVES

NCI, FDA Are Feuding Again, This Time Overcharge That DCT Moved Too Slowly On Toxicity Notification

This article is from The Cancer Letter archive.

Vol. 07 No. 15 | April 10, 1981

Download PDF Visit The Full Archive

Related Articles

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

May 8, 2013

Conversation with The Cancer Letter: Kazerooni: The Case for Broad Coverage

March 21, 2014

Program Announcement listed.

July 25, 2003

Cancer Screenings: American Over 50 Urged to Get Colon Caner Tests

March 5, 1999

FDA Commissioner Holds Up IND While Reviewing Toxicology Guidelines

August 14, 1981

ASH Highlights: Improved Treatments For NHL, Poor Prognostic Factors For B-Cell In Children

January 30, 2004